| Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406. | None |
| Single-molecule conformational analysis of G-quadruplex formation in the promoter DNA duplex of the proto-oncogene c-kit. | None |
| Dysregulated kit function is an important component of oncogenesis in a large number of neoplastic disorders, including systemic mastocytosis. | None |
| Trisubstituted isoalloxazines as a new class of G-quadruplex binding ligands: small molecule regulation of c-kit oncogene expression. | None |
| Kit oncogenic forms are responsible for ezrin phosphorylation | None |
| Expression of proto-oncogene C-kit and correlation with morphological evaluations in canine cutaneous mast cell tumors. | None |
| Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs). | None |
| Kit K641E oncogene up-regulates Sprouty homolog 4 and trophoblast glycoprotein in interstitial cells of Cajal in a murine model of gastrointestinal stromal tumours. | None |
| Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. | None |
| A G-rich sequence within the c-kit oncogene promoter forms a parallel G-quadruplex having asymmetric G-tetrad dynamics. | None |
| The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment. | None |
| Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene. | None |
| Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. | None |
| the ETS family member ETV1 is highly expressed in the subtypes of interstitial cells of Cajal sensitive to oncogenic KIT mediated transformation, and is required for their development | None |
| Activating mutations, specifically in NRAS, are found exclusively in advanced forms of systemic mastocytosis and may precede the proto-oncogene protein c-kit D816V mutation in clonal development. | None |
| Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. | None |
| Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells. | None |
| Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells. | None |
| The high rate of c-Kit/PDGFRA coexpression suggests that both receptors are involved in oncogenicity in gastrointestinal stromal tumors | None |
| Eng mRNA was up-regulated in Ba/F3 cell lines stably expressing various oncogenic Kit mutations. This effect appeared to be independent of Kit activation. | None |